During the corresponding time, T2 Biosystems Inc recorded a revenue increase by 34.85 % year on year, sequentially revenue grew by 1.69 %. While revenue at the T2 Biosystems Inc 's corporate clients
T2 Biosystems Inc's Comment on Sales, Marketing and Customers
The company primarily serves hospitals by marketing and selling the T2Dx Instrument and related panels, including T2Bacteria, T2Candida, and T2Resistance, directly within the United States and through exclusive distribution partners internationally. In the U.S., the target market includes hospitals focused on sepsis and antimicrobial resistance. Internationally, the company operates through distributors in Europe, Australia, the Middle East, Latin America, Asia Pacific, and Africa, who maintain relationships with key opinion leaders and major hospitals. Additionally, the company markets T2Biothreat directly to U.S. government defense agencies.
T2 Biosystems Extends Partnership with Vizient Despite Financial Instability LEXINGTON, Mass. In a move that underscores its commitment to addressing critical healthcare challenges, T2 Biosystems, Inc. (NASDAQ: TTOO), a pioneer in the rapid detection of sepsis-causing pathogens, has announced the extension of its multi-year capital equipment supplier agreement with Vizient, Inc. the largest member-driven health care performance improvement company in the United States. The agreement, which has now been extended through March 31, 2026, enables T2 Biosystems to continue providing its essential diagnostic tools to healthcare providers across the nation.The contract encompasses the T2Dx Instrument and its asso...
In a bold move marking its commitment to addressing global health challenges, T2 Biosystems, Inc. (NASDAQ:TTOO), a prominent player in rapid detection technologies for sepsis-causing pathogens, has announced significant commercial expansions into Southeast Asia and Europe. With exclusive distribution agreements in place for Malaysia, Indonesia, the Netherlands, Belgium, Vietnam, and Switzerland, the company is positioned to enhance its international footprint substantially. Expansion OverviewOn July 29, 2024, T2 Biosystems formalized a partnership with a new distributor that enables the sale of its sophisticated medical instruments and panels in Malaysia and Indonesia. This agreement brings the company’s ...
T2 Biosystems, a leading diagnostics company, has recently published a study highlighting the clinical benefits and performance of their groundbreaking T2Resistance Panel. This study has demonstrated that the utilization of T2Resistance Panel enables faster targeted therapy, providing a significant advantage in the battle against drug-resistant infections.The T2Resistance Panel is an innovative diagnostic tool that detects resistance genes directly from a patient s blood sample. This breakthrough technology eliminates the need for time-consuming and expensive culture-based methods, delivering results in a matter of hours rather than days. By swiftly identifying specific resistance genes, healthcare professio...
T2 Biosystems Joins NIH-funded Pilot Study to Revolutionize Pneumonia Detection through Innovative Diagnostic ApproachesLEXINGTON, Mass., Jan. 18, 2024 - T2 Biosystems, Inc. (NASDAQ: TTOO), a prominent leader in rapid detection technology for sepsis-causing pathogens and antibiotic resistance genes, has recently announced its participation in the Antibacterial Resistance Leadership Group (ARLG) pilot study funded by the National Institutes of Health (NIH). The study, known as the Pneumonia Direct Pilot, aims to explore new diagnostic approaches for ventilator-associated pneumonia (VAP) while also detecting antibiotic-resistant infections more comprehensively.Under the guidance of the renowned Dr. Kimberly Ha...
T2 Biosystems Inc’s Comment on Sales, Marketing and Customers
The company primarily serves hospitals by marketing and selling the T2Dx Instrument and related panels, including T2Bacteria, T2Candida, and T2Resistance, directly within the United States and through exclusive distribution partners internationally. In the U.S., the target market includes hospitals focused on sepsis and antimicrobial resistance. Internationally, the company operates through distributors in Europe, Australia, the Middle East, Latin America, Asia Pacific, and Africa, who maintain relationships with key opinion leaders and major hospitals. Additionally, the company markets T2Biothreat directly to U.S. government defense agencies.
Sources:
T2 Biosystems Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: T2 Biosystems Inc’s corporate clients.
For your research, we’ve provided 9 tables on T2 Biosystems Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
22.17 %